In contrast to the previous study, 5 of our osteosarcoma patient samples (20 %) did not show any aberration of TP53, RB1 or MDM2. But two of these samples showed MTAP rearrangement with CDKN2A co-deletion. Here, TP53 is linked to osteosarcoma.